GlobeNewswire
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
📊
AI Sentiment
Positive
7/10
- Home
- APRE
as of 02-17-2026 2:29pm EST
$0.56
$0.05
-8.88%
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | N/A |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 6.3M | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 6.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $3.71 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -80.5% | Revenue Growth (next year): | -65.20% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered APRE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.13%
70.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Aprea Therapeutics Inc. (APRE)
Gilad Oren
Buy
President/CEO
APRE Jan 30, 2026
Avg Cost/Share
$0.89
Shares
28,100
Total Value
$25,009.00
Owned After
373,720
SEC Form 4
Hamill John P.
Buy
SrVP/CFO/Prin Fin & Acct Ofcr
APRE Jan 30, 2026
Avg Cost/Share
$0.89
Shares
5,700
Total Value
$5,073.00
Owned After
33,433
SEC Form 4
Hamill John P.
Buy
SrVP/CFO/Prin Fin & Acct Ofcr
APRE Dec 10, 2025
Avg Cost/Share
$1.17
Shares
5,000
Total Value
$5,825.00
Owned After
33,433
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gilad Oren | APRE | President/CEO | Jan 30, 2026 | Buy | $0.89 | 28,100 | $25,009.00 | 373,720 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Jan 30, 2026 | Buy | $0.89 | 5,700 | $5,073.00 | 33,433 | |
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Dec 10, 2025 | Buy | $1.17 | 5,000 | $5,825.00 | 33,433 | |
| Duey Marc | APRE | Director | Dec 10, 2025 | Buy | $1.17 | 21,459 | $24,999.74 | 256,155 |
Latest Aprea Therapeutics Inc. News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
📈
AI Sentiment
Highly Positive
9/10
Compare APRE vs Leading Stocks
See how APRE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.